with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio) The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, MIT economist Andrew Lo and a16z General Partner on the Bio Fund Jorge Conde discuss how exactly we place an economic value on a cure; the questions we still need to figure out, like who should pay for what and how; and how we need to start thinking about handling the coming influx of highly priced medicines like these into our healthcare system. If we think about these payments as a kind of 'mortgage for a cure,' what happens when your gene therapy mortgage defaults? How would payment plans like these move between insurance plans? Lo and Conde also discuss the broader context in our healthcare system, the economics and risk of drug discovery and development overall – and finally, how our markets might just function more like biological systems than anything else.

with David Ulevitch (@davidu) and Sonal Chokshi (@smc90) Since the startup (and founder) journey doesn't go neatly linear from technical to product to sales, tightening one knob (whether engineering or marketing or pricing & packaging) creates slack in one of the other knobs, which demands turning to yet another knob. So how do you know what knob to focus on and when? How do you build the right team for the right play and at the right time? It all depends on "What time is it": where are you on the journey, and where do you want to go... In this episode of the a16z Podcast, general partner David Ulevitch (in conversation with Sonal Chokshi) shares hard-earned lessons on these top-of-mind questions for founders; as well as advice on other tricky topics, such as pricing and packaging, balancing between product visionary vs. product manager, how to manage your own time (and psychology!) as your company grows, and more. Much of this is based on his own up-and-down, inside-outside, big-small-big-small, long journey as CEO (and CTO) for the company he co-founded, OpenDNS. The company was later acquired by Cisco after it pivoted from consumer to enterprise. Speaking of, what are the latest shifts and nuances in selling and buying enterprise products, beyond the phrase "consumerization of enterprise"? Or beyond the cliché of "design thinking" -- how does one go beyond user experience and beyond things like fun gifs (which are pronounced, ahem, "jifs") to focusing on the whole customer experience, and earning the right to be complicated? All this and more in this episode... plus the magic 5 words that will help any CEO (and anyone, really). The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.